Being overweight and having high blood pressure tend to travel together. Carrying extra body weight forces the heart to work harder, raises blood vessel resistance, and over time pushes blood pressure into ranges that clinicians consider dangerous. It seems logical, then, that drugs designed to reduce body weight would also lower the cardiovascular risks that come with hypertension. A large Cochrane systematic review, searching trial registries and medical databases through April 2024, set out to test that assumption with hard numbers.
The review pooled results from eight randomized controlled trials involving roughly 13,000 adults who had been diagnosed with essential hypertension. Essential hypertension means persistently elevated blood pressure that is not explained by a single identifiable cause, which describes the vast majority of people living with the condition. Trials had to run for at least 24 weeks to qualify, and all of them compared an approved weight-management drug against a placebo.
What the researchers found was sobering in a specific way. It was not that the drugs failed to move the scale. It was that the existing trial data, even when pooled across thousands of participants, could not provide high-confidence answers about the outcomes that matter most to patients: survival and protection from heart attacks or strokes.
How the review was structured
The Cochrane team defined two tiers of outcomes. Critical outcomes were all-cause mortality, cardiovascular morbidity (which covers events like heart attacks and strokes), and adverse events. Important but secondary outcomes were changes in systolic and diastolic blood pressure and changes in body weight. This hierarchy matters because it signals what the reviewers considered clinically non-negotiable: keeping people alive and out of the hospital, not simply moving a number on a scale.
Five distinct drug interventions appeared across the eight trials: a fat-absorption blocker called orlistat, a combination of two appetite-affecting compounds called phentermine and topiramate, a combination of naltrexone and bupropion, the glucagon-like peptide-1 receptor agonist semaglutide, and the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide. Study durations ranged from six months to four years. Seven of the eight trials were funded by the pharmaceutical industry, which the review authors noted as a source of potential bias.
Findings on mortality and cardiovascular events
Across the board, the evidence for the most critical outcomes was graded as very low certainty. For orlistat, three deaths occurred in the treatment groups versus none in placebo groups across three trials, but with fewer than 1,500 participants and very low certainty, no meaningful conclusion could be drawn. For the phentermine-topiramate combination, no deaths occurred in either group, but again the evidence quality was rated very low. For naltrexone-bupropion, a large trial of more than 8,000 participants showed a risk ratio for all-cause mortality of 0.99, meaning virtually identical rates between drug and placebo, but that result also carried a very low certainty rating.
For cardiovascular morbidity, results were similarly inconclusive. The orlistat trials showed mixed numbers across two studies. The naltrexone-bupropion trial produced a risk ratio of 1.11 for cardiovascular events, slightly favoring placebo numerically, though the confidence interval crossed 1.0 and the evidence was again graded very low. The semaglutide and tirzepatide trials included in this review did not report outcomes for all-cause mortality, cardiovascular morbidity, serious adverse events, or all adverse events, which limited what the review could say about the two most recently approved agents.
Adverse event signals worth noting
While the mortality and cardiovascular data were largely inconclusive, the adverse event findings were more definitive in places. The review found moderate-certainty evidence that orlistat probably increases serious adverse events compared to placebo, with a risk ratio of 1.45 and a confidence interval ranging from 1.10 to 1.91. This is a meaningful signal because moderate certainty is a notable step up from the very low certainty attached to the critical outcomes.
The phentermine-topiramate combination probably increases overall adverse events compared to placebo, according to moderate-certainty evidence, though its effect on serious adverse events specifically was uncertain. Naltrexone-bupropion probably increases all adverse events, with a risk ratio of 1.69 and a narrow confidence interval, but showed little to no difference from placebo in serious adverse events specifically. The pattern across compounds suggests that tolerability varies meaningfully depending on which agent is studied.
Why the evidence gap exists
The review authors identified a structural problem in how the underlying trials were designed. None of the included trials had mortality or cardiovascular morbidity as their primary endpoint. Those outcomes showed up, when they appeared at all, as secondary safety data tucked inside adverse event tables rather than as pre-specified endpoints with adequate statistical power. That design choice means the trials were never built to detect differences in survival or heart disease, so the inability to find clear signals is not surprising.
A second problem is that most major cardiovascular outcome trials in this space enroll broad populations that include both people with normal blood pressure and people with hypertension. When results are not reported separately for the hypertensive subgroup, it becomes impossible to know whether blood-pressure-compromised participants responded differently from the general cohort. The review authors called explicitly for future trials to report stratified results so that the hypertensive population can be studied on its own terms.
The inclusion of semaglutide and tirzepatide as new additions to this fourth update of the review reflects how quickly the field is moving. Both compounds have attracted significant research attention for their effects on body weight and metabolic markers, but the specific trials that qualified for this review did not contribute data on the critical outcomes the Cochrane team was measuring. Larger, longer, and more targeted trials focused on hypertensive participants would be needed to fill that gap.
What the peptide science context adds
Semaglutide and tirzepatide belong to a class of compounds built around peptide biology. Semaglutide is a modified version of a naturally occurring gut hormone called glucagon-like peptide-1. When researchers administer it, it activates receptors in the brain and pancreas that reduce appetite, slow gastric emptying, and influence how the body handles blood sugar. Tirzepatide adds a second receptor interaction, targeting glucose-dependent insulinotropic polypeptide receptors alongside the same glucagon-like peptide-1 pathway. These dual actions have made it a subject of significant metabolic research.
The basic science behind these peptides suggests plausible mechanisms through which they might benefit people with hypertension. Reduced body weight lowers mechanical load on the cardiovascular system. Some research has pointed to direct effects of glucagon-like peptide-1 receptor activation on blood vessel tone and kidney function. But the Cochrane review illustrates a familiar gap in research: biological plausibility and mechanistic studies do not automatically translate into confirmed hard-outcome benefits in well-defined patient populations. That confirmation requires long, large, carefully designed randomized trials, and for the hypertension-specific population, those trials are still incomplete.
The bottom line from the review
The Cochrane team concluded that current evidence is insufficient to draw confident conclusions about whether pharmacological weight loss reduces the risk of mortality or cardiovascular morbidity in people with essential hypertension. That is not a conclusion about whether the drugs work in a general sense. It is a conclusion about what the existing trial infrastructure can and cannot prove for a specific and vulnerable population.
The review called for more trials with hypertensive participants as a dedicated focus, not just a subgroup, and for existing trial data to be reported in ways that allow hypertensive participants to be analyzed separately. Until that evidence accumulates, the literature suggests that the story for this population remains genuinely open. Researchers, clinicians, and the public all have reason to watch the next generation of trials closely.
